Form 4: Roivant Director Receives Equity Awards, Settles Taxes

Roivant Sciences Director James C Momtazee was granted annual equity awards and disposed of shares for tax withholding purposes.

Summary

• Director James C Momtazee acquired 14,524 restricted stock units (RSUs) of Roivant Sciences Ltd. common shares on September 10, 2025, as an annual award. These RSUs have a grant price of $0 and are scheduled to vest 100% on September 10, 2026.
• Mr. Momtazee also acquired 33,726 stock options to purchase common shares on September 10, 2025, with an exercise price of $13.77. These options are scheduled to vest and become exercisable 100% on September 10, 2026, and expire on September 09, 2035.
• Concurrently, 3,282 common shares were disposed of on September 10, 2025, at a price of $13.77 per share. This disposition was a "net settlement" by the issuer to satisfy applicable tax withholding obligations related to the vesting and settlement of previously granted common shares.
• Following these transactions, Mr. Momtazee beneficially owns 107,912 common shares directly and 33,726 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Slightly positive. The filing indicates routine insider compensation through equity awards, aligning director interests with shareholders. The share disposition is for tax purposes, which is a neutral event.

Positives

• The grant of restricted stock units and stock options to Director James C Momtazee aligns his interests with those of shareholders, incentivizing long-term performance.
• The awards are part of the company's established 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy, indicating a structured approach to executive compensation.

Negatives

• The disposition of 3,282 common shares was for tax withholding purposes, which is a routine event and not indicative of a negative outlook by the director.

Risks

• The vesting of both RSUs and stock options is subject to the reporting person's continuous service through September 10, 2026.

Future Outlook

The awarded restricted stock units and stock options are scheduled to vest 100% on September 10, 2026, contingent upon the director's continuous service. The stock options have an expiration date of September 09, 2035.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industry, where non-employee directors often receive equity-based compensation to align their interests with long-term shareholder value. The "net settlement" for tax withholding is also a common mechanism for managing tax liabilities associated with equity vesting.

Corporate Governance

Related Party Transactions

• The equity awards granted to Director James C Momtazee are considered related party transactions as they involve compensation to an insider, executed under the company's established compensation policies.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: The compensation structure for directors may set a precedent or reflect the broader compensation philosophy within the company.

Next Steps

• Continued service of Director James C Momtazee through September 10, 2026, for full vesting of equity awards.

Key Dates

Recommendation

This Form 4 details routine insider compensation and tax-related share disposition. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It primarily confirms the ongoing alignment of director incentives with shareholder interests.

Keywords

Roivant Sciences, ROIV, James C Momtazee, Director, SEC Form 4, insider transaction, equity awards, restricted stock units, stock options, executive compensation, share disposition, tax withholding